Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205 Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Deoxycytidine
  • Pancreatic Neoplasms

abstract

  • In patients with advanced pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone. Alternate targets other than EGFR should be evaluated for new drug development.

publication date

  • August 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2917315

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.25.7550

PubMed ID

  • 20606093

Additional Document Info

start page

  • 3605

end page

  • 10

volume

  • 28

number

  • 22